Australia

JOHNNY BIGG EXPANDS RETAIL PRESENCE WITH NEW CONCESSIONS IN BELK STORES

Providing on-trend fashion for big and tall men across the USA. SYDNEY, Jan. 14, 2025 /PRNewswire/ -- Johnny Bigg , a fashion-forward brand made specifically for big and tall men, is excited to announce its retail debut in five Belk stores. This milestone highlights ...

2025-01-15 12:34 1172

Hansen Strengthens Community Solar Reach Across the United States, Targets New Growth Opportunities

Hansen today partners with Community Solar developers across ten US states; primed to enter seven more as customer operations expand MELBOURNE, Australia, Jan. 14, 2025 /PRNewswire/ -- Hansen Technologies (ASX:HSN), a leading global provider of software and services to the energy, utilities, com...

2025-01-14 21:49 1172

TESSAN Unveils Latest Travel Charging Solutions at CES 2025, Reinforcing User-Centric Brand Philosophy

LAS VEGAS, Jan. 8, 2025 /PRNewswire/ -- At CES 2025, which opened on January 7 and runs untilJanuary 10, leading charging solution provider TESSAN captivated attendees with its latest travel charging solutions. The brand further solidified its commitment to a user-centric philosophy through engag...

2025-01-09 03:02 1376

Seeing Machines to showcase world-leading interior sensing solutions at CES 2025

CANBERRA, Australia, Jan. 8, 2025 /PRNewswire/ -- Seeing Machines Limited (AIM: SEE), the advanced computer vision technology company that designs AI-powered operator monitoring systems to improve transport safety, will showcase its world-leading interior sensing technology at the Consumer Electr...

2025-01-08 15:00 1294

Hanx Biopharmaceuticals, Ltd. Announces First Patient Dosing in First-in-Human Phase 1 Clinical Trial of HX044

WUHAN, China, Jan. 2, 2025 /PRNewswire/ -- Hanx Biopharmaceuticals, CO. Ltd, an innovative biotechnology company developing next-generation immunotherapies to address the challenges of unmet medical need diseases, today announced the first patient dosing inAustralia on Dec 30, 2024 for Phase 1 cl...

2025-01-03 01:43 2001

Social Media Ban in Australia: What Online Casinos Can Learn on Responsible Gambling Practices? - Insights from CasinoAus

SYDNEY, Dec. 23, 2024 /PRNewswire/ -- Australia's social media ban for under 16's is a revolutionary step in internet regulation, and highlights an opportunity for the online casino industry to prioritise safe and enjoyable user experiences. Accor...

2024-12-24 00:12 2241

CStone Announces Submission of Clinical Trial Application in Australia for CS2009, an Innovative PD-1/VEGF/CTLA-4 Trispecific Antibody

SHANGHAI, Dec. 22, 2024 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, announced today the submission of clinical trial application inAustralia for CS2009 (PD-1/VEGF/CT...

2024-12-23 08:00 1690

DAZN ADVANCES GLOBAL EXPANSION WITH ACQUISITION OF FOXTEL, A LEADING AUSTRALIAN SPORTS AND ENTERTAINMENT MEDIA GROUP

* Milestone deal for DAZN's position as the global home of sport. * This acquisition establishes DAZN's sports platform in Australia, one of the world's most attractive sports markets. * Foxtel Group will leverage DAZN's global reach, industry-leading technology and extensive content portfol...

2024-12-23 07:43 1722

Clarity expands its pipeline with a novel optimised FAP-targeted radiopharmaceutical

Highlights * Clarity has developed a proprietary fibroblast activation protein (FAP)-targeted radiopharmaceutical product that can be used with the perfect pairing of copper isotopes for the diagnosis and treatment of cancer. * The product, termed SAR-bisFAP, has shown strong tumour targeting...

2024-12-18 22:03 1453

SK bioscience Receives Approval for Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate

* SK bioscience's first mRNA vaccine candidate is expected to enter clinical trials inAustralia in February 2025, with interim results expected by 2026. * Joint R&D project between SK and CEPI includes up to USD 40 million in initial funding support from CEPI. * SK bioscience will respond to...

2024-12-12 21:00 1732

More than 96,000 respond to the first Global Cinema Federation Movie-Goer survey - 'New Box Office records will continue to be set, as supply meets demand'

* Customers largely prefer watching movies in cinemas, only 5% would rather wait to watch on streaming * Customers are seeking MORE action/adventures (59%) and comedies (53%) in cinemas SYDNEY, Dec. 12, 2024 /PRNewswire/ -- The Global Cinema Federation

2024-12-12 14:59 1272

Alma Expands Injectables Presence in APAC with Profhilo® Launch in Thailand

CAESAREA, Israel, Dec. 12, 2024 /PRNewswire/ -- Alma Lasers , a Sisram Medical company and a global leader in energy-based medical and aesthetic solutions, announced today the opening of its new subsidiary inThailand, alongside the launch of Profhilo®, a groundbreaki...

2024-12-12 09:00 1574

Lunit Marks Go-Live in Groundbreaking National AI Cancer Screening Program in BreastScreen NSW

Lunit INSIGHT MMG integrated into the clinical workflow of Australia's BreastScreen New South Wales to assist in reading approximately 31,000 mammography exams annually SEOUL, South Korea, Dec. 9, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer d...

2024-12-09 22:00 1613

Actinogen randomizes first US participant in XanaMIA phase 2b/3 Alzheimer's disease trial

* Late-stage trial in Alzheimer's opens 10 sites in US, with results due in 2025 and 2026 * Appoints US-based Chief Commercial Officer, Andrew Udell * Xanamem's unique ability to control brain cortisol draws widespread coverage in the Australian media. SYDNEY, Dec. 9, 2024 /PRNewswire/ -- A...

2024-12-09 21:00 1579

Seeing Machines releases the 2023-24 Guardian Insights Report, highlighting alarming trends in driver fatigue and distraction from around the world

Over 11.6 million risky driving events recorded across 3.6 billion kilometres of travel in 12 months * More than 600,000 instances of mobile device use while driving were detected * On average, Guardian captured over 51 fatigue events per hour and more than 5 distracted driving events every mi...

2024-12-04 13:00 1271

AV-Comparatives Announces 2024 Phishing Test Results: Avast and McAfee Excel in Yearly Assessment

INNSBRUCK, Austria, Dec. 3, 2024 /PRNewswire/ -- AV-Comparatives, a leading independent organisation for IT security testing, has published the results of its comprehensive 2024 phishing protection tests. Over the year, 1,000 phishing URLs were tested in four quarterly evaluations to measure the ...

2024-12-03 23:00 1702

Panaya and Tritusa Join Forces to Enhance SAP Testing in Australia

This partnership brings together Panaya's robust AI-powered Smart Testing platform and Tritusa's rich testing expertise to deliver superior testing outcomes for Australian enterprises HACKENSACK, N.J., Dec. 2, 2024 /PRNewswire/ -- Panaya , the leader in SaaS-based AI-Powe...

2024-12-03 06:00 1389

City of Kinston Enhances Utility Services with Hansen CIS Upgrade, Modernizing Customer Care and Billing

City of Kinston builds on its 26-year strong partnership with Hansen, upgrading its Customer Information System (CIS) to enhance customer care and billing experiences for its residents MELBOURNE, Australia, Nov. 21, 2024 /PRNewswire/ -- Hansen Technologies (ASX:HSN), a leading global provider of...

2024-11-21 22:00 1319

Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study

Highlights: * Positive preclinical results in human in vitro iPSC Motor Neuron models of Amyotrophic Lateral Sclerosis (ALS) * Neurizon's lead drug NUZ-001 and its major active metabolite significantly and dose-dependently prevented the aggregation of TAR DNA-binding protein 43 (TDP-43) by ~...

2024-11-19 20:30 1297

Neurizon Therapeutics Receives Positive Opinion on Orphan Medicinal Product Designation for NUZ-001 in Europe

Highlights: * Notice of positive opinion received from the European Medicines Agency for Orphan Medicinal Product Designation for NUZ-001 in Amyotrophic Lateral Sclerosis * Orphan Designation offers 10 years of market exclusivity in Europe upon product approval, along with additional regulat...

2024-11-11 20:30 1157
12345 ... 54